The MLL – Menin interaction is a therapeutic vulnerability in NUP98-rearranged AML
To investigate the effect of Menin inhibitor on patient-derived NUP98-r AML. We treated primary AML cells with Menin inhibitor in a Mesenchymal stem cell co-Culture platform. Then we charachterized global gene expression in treated AML cells upon treatment in two different time points, day7 and day12. Overall design: Comparative gene expression profiling analysis of RNA-seq data for patient-derived NUP98::NSD1 AML cells after treatment with Menin inhibitor (SNDX-5613/Revumenib).